Cargando...
New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent cellular cytotoxicity and direct cell death, leading to superior cytotoxicity compared with rituximab. The approval of obinutuzumab by US Food and Drug A...
Guardado en:
| Publicado en: | Ther Clin Risk Manag |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4524526/ https://ncbi.nlm.nih.gov/pubmed/26251607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S71839 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|